Yaz (Malaysia)

  • West Malaysia will receive between 05/12/2022 to 08/12/2022
  • East Malaysia will receive between 09/12/2022 to 12/12/2022

*6 item(s) sold

RM56.90


  • Free shipping for West Malaysia if purchase is above RM100
  • Buy 3 and above and get 6% off (Can mix and match)
  • Up to 3% cash back to store credit when you leave a review when the order is completed
Buy 3 units and above, get 6% off
1-2 RM56.90
3-89 RM53.49
90+ RM51.21

  • Authentic product KKM sticker (Malaysia health ministry sticker)
  • 28 tablets
  • Purchase today and ship out the next working day

Contents: Drospirenone 3 mg, ethinyloestradiol 0.03 mg

Dosage/Direction for Use: 1 tab daily on 1st day of menstrual cycle for 21 consecutive days followed by 7 tab-free days.

Contraindications:Adrenal insufficiency, current, suspected or history of breast cancer or other oestrogen- or progestin-sensitive cancer; presence of severe or multiple risk factors for venous or arterial thromboembolism (VTE/ATE) (e.g. DVT, pulmonary embolism, major surgery with prolonged immobilisation, MI, angina pectoris, cerebrovascular disease such as stroke or TIA; headaches with focal neurological symptoms, migraine headaches with or without aura if >35 years, diabetes mellitus with vascular symptoms, severe or uncontrolled hypertension, severe dyslipoproteinaemia, coronary artery disease, inherited or acquired hypercoagulopathies, thrombogenic valvular or heart rhythm diseases such as subacute bacterial endocarditis with valvular disease or atrial fibrillation; women >35 years who smoke, obesity [BMI >30 kg/m2]; known hereditary or acquired predisposition to VTE/ATE such as activated protein C [APC]-resistance, Factor V Leiden mutation, antithrombin-III-deficiency, protein C and S deficiency, hyperhomocysteinaemia, anti-phospholipid antibodies [e.g. anticardiolipin antibodies, lupus anticoagulant]; SLE with unknown or positive antiphospholipid antibodies); presence or history of hepatic tumours (benign or malignant), undiagnosed abnormal uterine/vaginal bleeding, acute viral hepatitis. Renal and hepatic impairment. Pregnancy. Concomitant use with hepatitis C drug combinations containing ombitasvir, paritaprevir/ritonavir with or without dasabuvir.

Special Precautions:Women with risk factors for CV disease (e.g. low HDL, high LDL or triglycerides); depression, prediabetes or diabetes mellitus, hypertriglyceridaemia, history of chloasma gravidarum, SLE, chronic inflammatory bowel disease, hereditary angioedema, history of pregnancy-related cholestasis, who are undergoing thyroid replacement therapy; who undergone specific bariatric procedures (e.g. Roux-en-Y, biliopancreatic diversion). Smokers. Not indicated for use prior to menarche, or in postmenopausal women. Not recommended for women with complicated organ transplants (e.g. graft failure, rejection, cardiac allograft vasculopathy). Lactation.